Search results
Results from the WOW.Com Content Network
ZF2001, trade-named Zifivax or ZF-UZ-VAC-2001, is an adjuvanted protein subunit COVID-19 vaccine developed by Anhui Zhifei Longcom in collaboration with the Institute of Microbiology at the Chinese Academy of Sciences. [2] [3] The vaccine candidate is in Phase III trials with 29,000 participants in China, Ecuador, Malaysia, Pakistan, and ...
Mitochondrial biogenesis is the process by which cells increase mitochondrial numbers. [ 1 ] [ 2 ] It was first described by John Holloszy in the 1960s, when it was discovered that physical endurance training induced higher mitochondrial content levels, leading to greater glucose uptake by muscles. [ 3 ]
COVID-19 vaccine clinical research uses clinical research to establish the characteristics of COVID-19 vaccines. These characteristics include efficacy , effectiveness , and safety. As of November 2022 [update] , 40 vaccines are authorized by at least one national regulatory authority for public use: [ 1 ] [ 2 ]
Mitochondrial replication is controlled by nuclear genes and is specifically suited to make as many mitochondria as that particular cell needs at the time. Mitochondrial transcription in humans is initiated from three promoters , H1, H2, and L (heavy strand 1, heavy strand 2, and light strand promoters).
By 11 May 2021, the WHO Weekly Epidemiological Update had reported 34 countries with detections of the subvariant, [18] however by 25 May 2021, the number of countries had risen to 41. [ 19 ] [ 20 ] As of 19 May 2021 [update] , the United Kingdom had detected a total of 418 confirmed cases of the SARS-CoV-2 Kappa variant. [ 21 ]
A nucleoside-modified messenger RNA (modRNA) is a synthetic messenger RNA (mRNA) in which some nucleosides are replaced by other naturally modified nucleosides or by synthetic nucleoside analogues.
The Moderna COVID‑19 vaccine, sold under the brand name Spikevax, is a COVID-19 vaccine developed by the American company Moderna, the United States National Institute of Allergy and Infectious Diseases (NIAID), and the Biomedical Advanced Research and Development Authority (BARDA).
While mRNA vaccines, such as the Pfizer–BioNTech COVID-19 vaccine and Moderna COVID-19 vaccine showed higher efficacy of +90%, mRNA vaccines present distribution challenges for some nations, as some may require deep-freeze facilities and trucks. By contrast, the BIBP vaccine can be transported and stored at normal refrigeration temperatures. [17]